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Neuroscience, University Medical Center Utrecht, Utrecht, The NetherlandsObjectives. The beneficial effect of oral anticoagulants after infrainguinal venous bypass surgery is compromised by
bleeding complications. We developed a model to identify patients, treated with anticoagulation, at risk of major
haemorrhage and estimated whether this complication could have been prevented if patients had received aspirin.
Design. Randomised clinical trial.
Methods. Data of patients who participated in the Dutch Bypass Oral Anticoagulation or Aspirin Study were reanalysed
using Cox regression. After infrainguinal bypass surgery these patients were randomised to oral anticoagulants (nZ1326)
or aspirin (nZ1324).
Results. Predictors of major haemorrhage for patients on oral anticoagulants were increased systolic blood pressure
(R140 mmHg, hazard ratio [HR] 1.62), ageR75 years (HR 2.77) and diabetes mellitus (HR 1.60). If the 345 patients in the
highest risk quartile had received aspirin, major haemorrhages would have been reduced from 46 to 22, with no major
changes in ischemic events and graft occlusions. In the subgroup with venous bypasses major haemorrhages would have been
reduced from 27 to 13, at the cost of seven more ischemic events (mostly fatal) and 17 more graft occlusions.
Conclusions. Treating patients at highest risk of major haemorrhage with aspirin instead of oral anticoagulants would have
resulted in a reduction of non-fatal haemorrhages, but for venous bypasses this reduction was outweighed by an increase in
ischemic events and graft occlusions. We still recommend treatment with oral anticoagulants after peripheral venous bypass
surgery.Keywords: Infrainguinal bypass; Prognosis; Haemorrhage; Anticoagulants; Antiplatelets.Introduction
The Dutch Bypass Oral anticoagulants or Aspirin
(BOA) Study has demonstrated that oral anticoagu-
lants are more effective than aspirin for the prevention
of occlusion of venous bypass grafts in patients with
atherosclerosis of the femorodistal arteries, hazard
ratio (HR) 0.69 (95% confidence interval (CI) 0.54–
0.88).1 Oral anticoagulant treatment tended to
decrease the total number of vascular ischemic deaths,ing author. Prof. A. Algra, MD, Department of
nd Julius Center for Health Sciences and Primary
ity Medical Center Utrecht, Str. 06.131, Heidelberglaan
85500, 3508 GA Utrecht, The Netherlands.
: a.algra@umcutrecht.nl
www.juliuscenter.nl
0154+ 06 $35.00/0 q 2005 Elsevier Ltd. All rights resermyocardial infarctions, cerebrovascular accidents and
amputations compared with aspirin: HR 0.89 (95% CI
0.75–1.06). Fatal bleeding complications and haemor-
rhagic strokes were included in this composite end-
point. On the other hand, there was a two-fold
increased risk of all bleeding complications in the
patients treatedwith oral anticoagulants: HR 1.96 (95%
CI 1.42–2.71). Health care costs, event-free survival,
and quality-adjusted life years in patients after
infrainguinal bypass surgery were not different in
patients treated with aspirin and patients treated with
oral anticoagulants. The extra costs of monitoring
patients treated with oral anticoagulants were limited
and play no role in the decision for treatment.2
This fragile balance of beneficial antithrombotic
effects and adverse bleeding events emphasises theEur J Vasc Endovasc Surg 30, 154–159 (2005)
doi:10.1016/j.ejvs.2005.03.005, available online at http://www.sciencedirect.com onved.
Major Haemorrhage after Infrainguinal Bypass 155need for monitoring the optimal intensity of anti-
coagulant treatment, to offer the best risk–benefit ratio,
i.e. the optimal balance of ischemic and haemorrhagic
events. The optimal target range of international
normalized ratio (INR) for these patients after infra-
inguinal bypass surgery appeared to be an INR
between 3 and 4.3
To further minimize the risk of oral anticoagulant
treatment it is important to identify risk factors and
quantify their predictive values for bleeding compli-
cations. Previous studies have searched for risk factors
for major haemorrhage in patients on oral anti-
coagulation.4–9 In two of these studies, the authors
developed a model to predict bleeding compli-
cations.5–7 Predictors of bleeding complications were
increasing age, male sex, malignancy and history of
gastrointestinal tract bleeding, history of stroke and
one of the following co-morbidities: recent myocardial
infarction, renal insufficiency, severe anaemia at
discharge or diabetes mellitus. Both risk scores were
developed in outpatients treated with oral anti-
coagulation. Hence, the authors could not study
whether the bleeding complications could have been
prevented if these patients had received other anti-
thrombotic drugs.
The aim of the first part of the present study was to
develop a model to predict major haemorrhage in
patients who received anticoagulant therapy after
infrainguinal bypass surgery to identify the group at
highest risk. In the second part of this study, it was
estimated whether in patients at highest risk of major
haemorrhage these haemorrhages could have been
prevented if patients would have received aspirin.
Furthermore, the number of ischemic events and graft
occlusions on oral anticoagulation and on aspirin are
estimated in the group at highest risk of major
haemorrhage.MethodsStudy population
All patients from the Dutch BOA Study were subjects
of the current study. The Dutch BOA Study was a
multicentre randomised trial in which the effective-
ness of oral anticoagulants (phenprocoumon or ace-
nocoumarol INR 3.0–4.5) was compared with that of
aspirin (80 mg daily) in the prevention of graft
occlusions and other thrombotic events after infra-
inguinal bypass grafting. Background, design, and
results of the trial have been reported elsewhere.10
Between April 1995 and March 1998, 1326 patientswere randomised to oral anticoagulant treatment and
1324 to aspirin treatment. Patients were assessed 3 and
6 months after surgery and every 6 months thereafter.Study outcome
The outcome of interest of the first part of the study
was major haemorrhage. It was defined as fatal
bleeding, intracranial haemorrhage, or any bleeding
requiring hospital attendance, irrespective of inter-
ventions. Postoperative bleeding episodes were not
included in the analyses because of frequent modifi-
cations in antithrombotic therapy perioperatively and
because these episodes may be related to surgery
rather than allocated antithrombotic treatment.
The outcome of the interest of the second part of the
study was major haemorrhage classified as described
above, ischemic events classified as non-fatal myocar-
dial infarction, non-fatal ischemic stroke or vascular
ischemic death, and infrainguinal graft occlusions.10Data AnalysisFirst part
For approximately 20% of the patients data for systolic
blood pressure was missing. Linear regression anal-
ysis with the variables age, history of hypertension,
history of myocardial infarction, history of transient
ischemic attack or ischemic stroke, smoking and
hyperlipidemia was used to impute the missing data
on systolic blood pressure.
Univariable associations between potential predic-
tors and the occurrence of major haemorrhage were
assessed with Cox regression analyses and expressed
as HRs with corresponding 95% CIs.
Candidate predictor variables associated with
major haemorrhage in the univariate analyses
(p value %0.20) were selected. The selected variables
were entered into multivariable Cox regression ana-
lyses with forward stepwise selection to develop a
multivariable prognostic model. The variables systolic
blood pressure and age were categorized in the
multivariable analyses to develop a prediction model
that could be applied easily in clinical practice.
To adjust for overfitting we performed bootstrap-
ping.11 Bootstrapping replicates the process of sample
generation from an underlying population by drawing
samples with replacement from the original data set,
of the sample size of the original data-set.12 With
bootstrapping the internal validity can be estimated.11
Finally, a risk score was constructed and categorizedEur J Vasc Endovasc Surg Vol 30, August 2005
Table 1. Univariable associations of potential predictors with major haemorrhage in patients on oral anticoagulation after infrainguinal
bypass surgery
Variables Major haemorrhage HR 95% CI p value
Yes (nZ108) No (nZ1218)
Sex (men) 62 (57%) 797 (65%) 0.76 0.52–1.11 .15*
Mean age (SD) (HR per SD (10 years)) 72 (10) 68 (10) 1.49 1.21–1.84 .00*
Mean systolic blood pressure (SD)
(HR per SD (26 mmHg))
165 (24) 160 (27) 1.18 0.99–1.40 .07*
Systolic blood pressureR140 mmHg 96 (89%) 983 (81%) 1.84 1.01–3.35 .05*
History of
Hypertension 47 (44%) 485 (40%) 1.11 0.76–1.63 .58
Diabetes mellitus 40 (37%) 312 (26%) 1.73 1.17–2.56 .01*
Hyperlipidemia 16 (15%) 195 (16%) 0.91 0.53–1.54 .71
Transient ischemic attack or stroke 14 (13%) 146 (12%) 1.19 0.68–2.08 .55
Angina pectoris 18 (17%) 196 (16%) 1.00 0.61–1.67 .99
Myocardial infarction 20 (19%) 201 (17%) 1.20 0.74–1.95 .46
Smoking 47 (44%) 668 (55%) 0.63 0.43–0.92 .02*
Type of bypass (femorocrural graft vs.
femoropopliteal graft)
46 (43%) 496 (41%) 1.47 0.95–2.27 .08*
Bypass material (non-venous vs. venous) 27 (25%) 229 (19%) 1.09 0.74–1.60 .66
SD, standard deviation.
* Variables with a p value%0.20 were introduced in the multivariable Cox regression analyses with stepwise forward selection.
M. J. Ariesen et al.156into quartiles of risk of major haemorrhage. Kaplan–
Meier methods were used to estimate the cumulative
proportion of patients with major haemorrhage.Second part
To evaluate the distribution of events, if patients at
highest risk of major haemorrhage on oral anti-
coagulants had received aspirin, the observed num-
bers of major haemorrhages, ischemic events and graft
occlusions in the patients in the highest risk group
were compared with the observed numbers in patients
with the same characteristics who received aspirin.
The numbers were reported separately according to
graft material, since the main report of the Dutch BOA
Study demonstrated that oral anticoagulation was
more effective for the prevention of graft occlusion in
patients with a venous bypass and aspirin more
effective in patients with a non-venous bypass.10Table 2. Independent predictors of risk of major haemorrhage in pa
Variable Hazard ratio 95% CI
Age
%60 years 1 (ref.)
61–74 years 1.56 0.83–2.94
R75 years 2.77 1.46–5.25
Systolic blood pressure
!140 mmHg 1 (ref.)
R140 mmHg 1.62 0.89–2.97
History of diabetes mellitus
No 1 (ref.)
Yes 1.60 1.08–2.37
CI, confidence interval.
* Regression coefficients of the multivariable model were shrunken w
Eur J Vasc Endovasc Surg Vol 30, August 2005ResultsFirst part
The risk of major haemorrhage was 4.9% per year (95%
CI 4.0–5.8%) for patients on oral anticoagulation; 108
major haemorrhages occurred in 2192 person years.
The mean follow-up time was 1.7 years. Factors that
were associated with major haemorrhage in patients
on oral anticoagulation in the univariate analyses were
male sex, increasing age, increasing systolic blood
pressure, diabetes mellitus, smoking and a femoro-
crural bypass (Table 1).
In the multivariable Cox regression analyses, age
(R75 years, HR 2.77), hypertension (systolic blood
pressureR140 mmHg, HR 1.62) and diabetes mellitus
(HR 1.60) were predictors of major haemorrhage
(Table 2). After bootstrapping the regression coeffi-
cients were shrunk by 7% to adjust for overfitting.tients on oral anticoagulation after infrainguinal bypass surgery
p value Coefficients after
shrinkage*
Score
.001 0 0
0.41 4
0.94 9
.12 0 0
0.44 4
.02 0 0
0.44 4
ith bootstrapping to adjust for overfitting.
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Major Haemorrhage after Infrainguinal Bypass 157From the shrunken regression coefficients a risk score
was computed (range 0–17) and categorized into
quartiles (Q1–Q4) of the total population: Q1: 0–4;
Q2: 8; Q3: 9–12 and Q4: 13–17 (Table 3).n
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In the patients on oral anticoagulants the annual risk of
major haemorrhage was 9.0% for the group with a
score in the fourth quartile (nZ345) and 43% of all
major haemorrhages occurred in this group (Table 3
and Fig. 1).
The number of major haemorrhages that would
have occurred in these 345 patients, in the highest risk
quartile of major haemorrhage, if they had received
aspirin would have reduced from 46 to 22 (Table 4).
The number of fatal bleeds would not have altered.
The number of ischemic events that would have
occurred with aspirin was estimated to be 76 instead
of the observed 75 ischemic events. The number of
graft occlusions would have been similar.
For patients with a venous graft only (nZ202
(59%)), non-fatal major haemorrhage would have
been reduced from 27 to 13 cases. However, in
patients with a venous bypass the number of fatal
haemorrhages would have increased from 1 to 2, non-
fatal ischemic events from 8 to 9 events and graft
occlusions from 25 to 42 events. The number of
vascular ischemic deaths would have increased from
35 to 41.T
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In the Dutch BOA Study, oral anticoagulants improved
venous bypass patency at cost of more major bleeding
episodes. If patients at highest risk of major haemor-
rhage on oral anticoagulation with a venous bypass
had received aspirin, less major non-fatal haemor-
rhages would have occurred. However, this benefit
would have been at the cost of more vascular ischemic
deaths, non-fatal ischemic events and graft occlusions.
Therefore, we conclude that even patients with a
venous bypass, at highest risk of major haemorrhage,
should be treated with oral anticoagulation.
Age, systolic blood pressure and diabetes mellitus
are predictors of risk of major haemorrhage in patients
treated with oral anticoagulants after infrainguinal
bypass surgery. The results of this study are supported
by results from previous studies in various patients
with vascular disease treated with oral anticoagula-
tion, that have shown that older age is associated with
increased occurrence of major haemorrhage.4,6,9,13Eur J Vasc Endovasc Surg Vol 30, August 2005
    
 
 
 
 
  
Fig. 1. Cumulative proportion of major haemorrhage per
score category in patients on oral anticoagulation after
infrainguinal bypass surgery.
M. J. Ariesen et al.158Furthermore, hypertension was found to be associated
with major haemorrhage.13 One study in outpatients
on oral anticoagulation showed that older age and
diabetes mellitus were predictive of risk of major
haemorrhage.5 Furthermore, diabetes mellitus also
was shown to be associated with intracerebral
haemorrhage.14
A limitation of our study is that data from a trial
were used to develop a model. For prognostic studies
one prefers observational cohort data and not trial
data, since in a trial predictors might have been more
carefully measured than in normal clinical practice.
Moreover, a trial population may not be reflective of
the normal population. However, in this study, the
predictors of major haemorrhage were age, systolicTable 4. Number of major haemorrhagic events and major ischemic e
anticoagulation and number if these 345 patients would have rece
bypass
All patients in Q4
(NZ345)
Oral
anticoagulation
Aspirin
Major haemorrhages 46 22
Fatal haemorrhage 4 4
Non-fatal haemorrhage
Intracranial haemorrhage 3 0
Gastrointestinal 21 9
Urinary 8 5
Other 10 4
Major ischemic events 75 76
Vascular ischemic death 58 57
Non-fatal ischemic events
Ischemic stroke 7 10
Myocardial infarction 6 5
Infrainguinal bypass occlusions 73 73
Eur J Vasc Endovasc Surg Vol 30, August 2005blood pressure and diabetes mellitus. These charac-
teristics were extracted from the patients’ medical
record and therefore it is unlikely that these would
have been different from those measured in routine
clinical practice. Moreover, the trial protocol was
pragmatic with patient inclusion and data registration
conforming to routine practice. Another limitation of
this study was that systolic blood pressure was not
reported for all patients. Therefore, we imputed the
missing systolic blood pressure with linear regression.
To verify the imputation procedure, the mean systolic
blood pressure before and after imputation were
compared and appeared to be the same. Furthermore,
the association with major haemorrhage appeared the
same before and after imputation and the point
estimates of the co-variables in the model appeared
almost similar. Therefore, the imputation was con-
sidered to be adequate and we chose to include
systolic blood pressure in the multivariable model.
Although systolic blood pressure was not associated
significantly with major haemorrhage, at a p-value cut-
off of 0.05, inclusion of systolic blood pressure
increased the discriminative power of the model.
We performed bootstrapping to internally validate
our model. Optimal estimates of internal validity of
regression models are obtained with bootstrapping.11
Internal validation refers to the performance of a
model in patients from a similar population from
which the sample originated. In this study after
bootstrapping the regression coefficients were shrunk
minimally, by approximately 7%, indicating accepta-
ble internal validity.
In conclusion, our model identified a subgroup of
patients on oral anticoagulation at highest risk of
major haemorrhage. It does not appear to be beneficialvents in patients at highest risk (Q4) of major haemorrhage on oral
ived aspirin and numbers for patients at high risk with a venous
Patients in Q4 with venous bypass
(NZ202 of 345 patients (59%))
Difference Oral
anticoagulant
Aspirin Difference
K24 27 13 K14
Z 1 2 C1
K3 2 0 K2
K12 15 5 K10
K3 4 3 K1
K6 5 3 K2
C1 43 50 C7
K1 34 39 C5
C3 4 6 C2
K1 4 3 K1
Z 25 42 C17
Major Haemorrhage after Infrainguinal Bypass 159to treat the high risk venous bypass patients with
aspirin instead of oral anticoagulants as any reduction
of major non-fatal haemorrhage would be outweighed
by an increase in ischemic events and graft occlusions.
Therefore, the optimal treatment should still be
determined according to bypass graft material: oral
anticoagulants for venous graft and aspirin for
prosthetic grafts.Acknowledgements
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